Jon Faiz Kayyem - May 29, 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INXB)

Role
Director
Signature
/s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., as attorney-in-fact
Stock symbol
INXB
Transactions as of
May 29, 2024
Transactions value $
$0
Form type
4
Date filed
5/30/2024, 06:10 PM
Previous filing
May 24, 2024
Next filing
May 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INXB Common Stock Award +806K 806K May 29, 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F1, F2
transaction INXB Common Stock Award +6.25K 6.25K May 29, 2024 By Child A F1, F3
transaction INXB Common Stock Award +6.25K 6.25K May 29, 2024 By Child B F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INXB Stock Option (right to buy) Award $0 +30K $0.00 30K May 30, 2024 Common Stock 30K $15.86 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.
F2 These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F3 These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F4 These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F5 This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
F6 This stock option will be fully exercisable on May 30, 2025, subject to the reporting person?s continued service through such date.